Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656120 | 0.87 | PKM (0.45) | LMNAALDH1A1TSHRUSP2GAA | |
| SCHEMBL1656155 | 0.84 | MMP1 (0.48) | LMNAALDH1A1TSHRUSP2GAA | |
| SCHEMBL2927356 | 0.79 | PKM (0.43) | LMNAALDH1A1TSHRUSP2GAA | |
| SCHEMBL1656842 | 0.79 | MMP1 (0.47) | LMNAALDH1A1TSHRUSP2GAA | |
| SCHEMBL29228879 | 0.78 | PKM (0.53) | LMNAALDH1A1TSHRUSP2GAA | |
| SCHEMBL1655573 | 0.72 | MMP1 (0.40) | LMNAALDH1A1TSHRUSP2GAA | |
| SCHEMBL10788602 | 0.69 | ADORA1 (0.42) | ALDH1A1TP53 | |
| SCHEMBL7047558 | 0.69 | NOD2 (0.47) | NOD2NOD1LMNAALDH1A1TSHR | |
| SCHEMBL8247399 | 0.68 | ESR1 (0.63) | CA1CA2CA7CA9CA14 | |
| SCHEMBL986133 | 0.68 | ESR1 (0.71) | CA1CA2CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768979-B1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | MERCK SERONO SA (CH) | 2010-09-29 | — | — | EP | claimed |
| EP-1303631-B9 | BIOTRANSFORMATION OF BIOLOGICALLY ACTIVE COMPOUNDS MADE OF VARIOUS CLASSES OF CHEMICAL SUBSTANCES BY MEANS OF LACCASE AND MANGANESE PEROXIDASE ENZYMES | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2010-09-08 | — | — | EP | claimed |
| EP-1303631-B1 | BIOTRANSFORMATION OF BIOLOGICALLY ACTIVE COMPOUNDS MADE OF VARIOUS CLASSES OF CHEMICAL SUBSTANCES BY MEANS OF LACCASE AND MANGANESE PEROXIDASE ENZYMES | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2010-05-26 | — | — | EP | claimed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | claimed |
| EP-1768979-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-04 | — | — | EP | claimed |
| WO-2006008303-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-01-26 | — | — | WO | claimed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| EP-1768979-B1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | MERCK SERONO SA (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-1768979-B1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | MERCK SERONO SA (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| EP-1768979-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008303-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006008303-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | PNPO, NLRP3, CHRM3 | NOD2 244/4885NOD1 13/4885LMNA 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.